海泰新光(688677.SH)：2025年度净利润1.72亿元，同比增长26.79%

Core Viewpoint - The company reported a strong performance for the fiscal year 2025, with significant growth in revenue and net profit, indicating robust operational stability despite external challenges [1] Financial Performance - The company achieved an operating revenue of 603 million yuan, representing a year-on-year increase of 36.08% [1] - The net profit attributable to the parent company was 172 million yuan, reflecting a year-on-year growth of 26.79% [1] - The net profit excluding non-recurring gains and losses was 166 million yuan, with a year-on-year increase of 28.67% [1] Operational Strategy - In response to the risks posed by U.S. tariffs on Chinese goods, the company has actively adjusted its production strategies, with most products now being manufactured and shipped from its factories in the U.S. and Thailand [1] - The company has coordinated production between domestic and overseas factories to mitigate the impact of tariffs, leading to a significant increase in the export scale of medical endoscope products [1] - Increased investment in research and market development for proprietary brand products has laid a solid foundation for the growth of the complete machine business [1] Business Segments - The optical business segment experienced rapid sales growth during the reporting period [1]